In the realm of modern healthcare, the convergence of pharmaceuticals, medical devices, and biologics has given birth to a remarkable class of medical interventions known as combination products (1). Combination products have the potential to give greater therapeutic benefits than single-entity devices such as medicines and biologics (2). Combination products are therapeutic and diagnostic things that contain a combination of medications, devices, and/or biological elements (3).

These innovative and multifaceted healthcare solutions have reshaped the landscape of patient care, offering novel treatment modalities that hold great promise (4). From drug-eluting stents to combination vaccines, combination products have demonstrated their potential to enhance therapeutic outcomes, improve patient adherence, and address some of the most challenging healthcare issues (5).

Figure 1 is visually represents the intricate process of developing combination products, which integrate drugs, devices, and biologics to create innovative healthcare solutions. Figure likely outlines the various stages of development, from conceptualization to market launch, illustrating key steps such as research, design, regulatory approval, and manufacturing. It serves as a visual guide, highlighting the collaborative efforts required among interdisciplinary teams to navigate the complexities of combination product development effectively.

The significance of combination products in healthcare lies not only in their ability to deliver integrated and synergistic treatments but also in their potential to address unmet medical needs (6). By bringing together different therapeutic approaches, they offer unique advantages that can translate into improved patient quality of life and better clinical outcomes (7). The ever-increasing pace of innovation in this field underscores their importance as a driving force in the ongoing advancement of medical science (8).

However, this promise comes with a critical caveat: the need for stringent regulatory oversight. The amalgamation of drugs, devices, and biologics in combination products creates a complex and multifaceted landscape where safety and efficacy are paramount (9). Ensuring that these products deliver their intended benefits without causing harm requires a meticulous and multifaceted approach to regulatory control (10).

Regulatory authorities, such as the U.S. Food and Drug Administration (FDA) and their counterparts worldwide, play a vital role in safeguarding public health (11). They navigate complex and evolving landscapes to establish regulatory frameworks that govern combination products, a class of medical interventions that do not fit neatly into traditional categories (12). The importance of this oversight cannot be understated, as it is inextricably linked to patient safety and the efficacy of these innovative medical solutions (13).

Regulatory Operations' Significant Obstacles. Some of the factors to consider when navigating the regulatory operations for drug-device combos are like: Keeping up-to-date with recent regulatory standards and revisions, recognizing product categorization and regulatory pathways, Taking care of the scientific and technical requirements, Patient care as well as usability testing, Considerations after the market (14, 15). Regulatory challenges in the realm of combination products arise from their unique nature, blending drugs, devices, and biologics, and require manufacturers and regulatory agencies to address several key complexities (16). These challenges include the intricate process of classifying these products, determining their primary mode of action (PMOA), and choosing the appropriate regulatory pathway (17). Overlapping regulations further complicate matters, with some combination products falling under the purview of multiple regulatory authorities (18). For instance, devices combined with biologics may be subject to both device and biologics regulations. The rapid evolution of healthcare technology adds to the challenge, with the integration of digital technologies in combination products demanding adaptive regulatory guidelines (19). post-market surveillance for ongoing safety and efficacy, along with the need to harmonize international regulations for global market entry, introduce additional complexities. To illustrate, consider the example of drug-eluting stents, where classifying these combination products requires a nuanced assessment of the mechanical action of the stent and the pharmacological action of the drug component (20). Furthermore, wearable combination products like insulin pumps challenge traditional regulatory boundaries, necessitating updated guidelines to accommodate technological innovations (21). Combination vaccines require comprehensive post-market surveillance, given the complexity of managing different components' adverse events and interactions (22). To overcome these regulatory challenges, collaboration between manufacturers and regulatory authorities, interdisciplinary expertise, and staying informed about evolving regulations are essential to ensure the safety and efficacy of combination products (23).

Figure 2 provides readers with a visual representation of the multifaceted regulatory challenges inherent in the development and approval of combination products, emphasizing the importance of comprehensive regulatory strategies and collaboration in addressing these challenges effectively.

The regulatory framework for combination products involves a meticulous process governed by the U.S. Food and Drug Administration (FDA) and other relevant regulatory authorities globally (37). In the United States, the FDA plays a central role, with the Office of Combination Products determining the primary mode of action to assign the appropriate regulatory pathway (38). This classification influences whether the product follows drug, device, or biologic regulations. The FDA collaborates with multiple centers, including the Center for Drug Evaluation and Research (CDER) and the Center for Devices and Radiological Health (CDRH), emphasizing an integrated approach to address safety and efficacy across diverse product components (39). The classification further guides the approval processes, with drug-dominated products following New Drug Application (NDA) or Biologics License Application (BLA) pathways, device-dominated products undergoing Premarket Approval (PMA) or 510(k) processes, and balanced products navigating a customized pathway based on primary mode of action (40). This intricate regulatory framework underscores the importance of collaboration, transparency, and adherence to evolving guidelines to ensure the effective development, evaluation, and approval of combination products that meet rigorous safety and efficacy standards (41).

Table 2 A comprehensive comparison of combination product regulations, aiding in navigating the regulatory landscape in different jurisdictions.

Safety considerations for combination products are of paramount importance, given their intricate fusion of drugs, devices, and biologics. These products introduce unique challenges as they may present unforeseen interactions and synergies. Potential risks and adverse events must be thoroughly explored, encompassing issues related to compatibility, potential device malfunctions, and the specific pharmacological effects of the incorporated drugs or biologics (42). Comprehensive risk assessment is crucial throughout the product life cycle, from development to post-market surveillance. Manufacturers must employ rigorous strategies to mitigate identified risks, ensuring user safety and product effectiveness (43). The importance of clear communication and education for healthcare professionals and patients cannot be overstated, contributing to informed use and proper risk management (44). Regulatory agencies play a vital role in overseeing these considerations, emphasizing a proactive and collaborative approach among manufacturers, healthcare providers, and regulatory bodies to ensure the highest standards of safety for combination products (45).

The Adverse Event (AE): Key Definitions (Source: ICH E2A) -Any adverse medical event that occurs in a patient or clinical research participant who is given a pharmaceutical product; the event need not be directly related to the treatment and same time (21 CFR 820.3) complaint -Any written, electronic, or spoken communication that makes assertions regarding the identity, composition, reliability, robustness, safety, effectiveness, or usage of a device after it is released for public use (46).

Evaluating the efficacy of combination products involves a multifaceted approach that considers the integrated performance of drugs, devices, and biologics. Clinical trials form a cornerstone, employing rigorous methodologies and diverse endpoints to comprehensively assess the product's effectiveness (47). The selection of appropriate endpoints depends on the primary mode of action; with clinical, physiological, or patient-reported outcomes being common measures (48). Post-market surveillance is essential for continuous efficacy assessment, monitoring real-world performance and potential long-term effects. Recent advancements emphasize the integration of digital technologies, such as real-world evidence and wearable devices, offering dynamic insights beyond traditional trial settings (49). Best practices include the establishment of robust post-market surveillance systems, close collaboration between manufacturers and regulatory authorities, and ongoing adaptation to emerging methodologies, ensuring a thorough and contemporary evaluation of the efficacy of combination products (50).

Drug Container Closure and Device Constituent Part Evaluations Are Included in Biological Safety Assessments for Drug-Device Combination Products. Both device and drug-based packaging standards have been deemed applicable when drug delivery systems and drug container closure systems are included in the device's constituent parts (51).

In contrast to pharmaceutical package delivery systems, other methods are employed for the bioassessment of medical equipment. Among the variations is the application of toxicological evaluation and chemical characterization either in place of or in addition to biological in vivo/in vitro testing (52). There are variations in how nonclinical research is used to evaluate a drug delivery system's or medical device's safety. Confusion has resulted from the absence of standardization in standards and recommendations about the testing and evaluation methodologies that make up a bioassessment that satisfies regulatory criteria for a medicinal device combination product (53).

Regulators, authorities, and outside parties should be consulted by manufacturers of combination items in India. The effectiveness or safety of the product should be proven by the manufacturer for each component. Multi-factorial research is often required for this, in which each factor is evaluated individually and in conjunction with a placebo control. Manufacturers must clearly justify every proposed active ingredient combination with a sound clinical explanation (54).

Goods like auto injectors, inhalers, pre-filled syringes, pre-filled pens for nebulizers, and transdermal patches are examples of drug-device combination goods. The following are some recommendations for creating combo items in India: •

Define the primary mode of action (PMOA)

The Drugs and Cosmetics Act of 1940 and the Drugs and Cosmetics Rules of 1945 govern combination goods in India. Additionally, called Fixed Dose Combinations (FDCs), they are. Medical device regulation is handled by the Drug Controller General of India (DCGI) under the Central Drugs Standard Control Organization (CDSCO). No person or business may enter into a combination that has or is likely to have a negative impact on competition in the relevant Indian market, according to Section 6 of the Act. A combination's active ingredients ought to all function for about the same amount of time. If not, the applicant must provide an explanation and justification for the combination. As part of the Plant Master File (PMF) application procedure, the ISO 13485 certification is necessary to validate the quality system(s) of the legitimate and/or real production facilities (15).

Table 3 facilitates comprehension of the regulatory framework in India, aiding stakeholders in navigating the regulatory landscape and ensuring compliance with applicable regulations for combination products.

Future directions in the field of combination products hold promise and challenges, shaped by emerging trends and technological advancements. Collaboration between regulatory bodies and industry stakeholders is likely to intensify, fostering the development of harmonized global standards to streamline the regulatory process. The integration of digital technologies, such as real-world evidence and smart devices, is poised to revolutionize efficacy assessments and post-market surveillance, providing richer and more dynamic data sets (56–58).

Regulatory changes may focus on refining classification processes and creating more tailored pathways for combination products. The need for increased flexibility to accommodate evolving technologies and interdisciplinary innovations may drive regulatory frameworks to become more adaptive and responsive (56).

Additionally, the emphasis on patient-centric healthcare may lead to enhanced patient involvement in the development and monitoring of combination products. Patient-reported outcomes and experiences could become integral components of efficacy assessments, reflecting a broader shift toward personalized and patient-centered care.

As technological advancements continue, manufacturers may explore novel combinations, such as integrating advanced biomaterials or incorporating artificial intelligence into combination products. This could usher in a new era of smart and responsive healthcare solutions.

The dynamic landscape of combination products presents a complex interplay of regulatory challenges, safety considerations, and efficacy assessments. Manufacturers must navigate the intricate classification processes and collaborate seamlessly with regulatory bodies, particularly the FDA, to ensure a streamlined and comprehensive approach. Safety considerations demand meticulous risk assessment and mitigation strategies to address potential complications arising from the amalgamation of drugs, devices, and biologics. the development and regulation of combination products stand at the forefront of innovation in healthcare, offering immense potential to improve patient outcomes and address complex medical challenges. However, realizing this potential requires a concerted effort from manufacturers, regulators, healthcare professionals, and patients alike.

Navigating the intricate regulatory landscape, addressing safety considerations, and evaluating efficacy are paramount to ensuring the success of combination products. Collaboration between regulatory agencies, interdisciplinary expertise, and adherence to evolving guidelines are essential for meeting rigorous standards and fostering trust in these innovative therapies.

As we look towards the future, continued collaboration, regulatory harmonization, and technological advancements will be key drivers of progress in the field of combination products. By prioritizing patient safety, embracing innovation, and maintaining a commitment to excellence, we can unlock the full potential of these transformative medical interventions, ultimately improving the lives of patients around the world.